Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D(3) as host directed therapy

BACKGROUND: We have previously shown that 8 weeks’ treatment with phenylbutyrate (PBA) (500mgx2/day) with or without vitamin D(3) (vitD(3)) (5000 IU/day) as host-directed therapy (HDT) accelerated clinical recovery, sputum culture conversion and increased expression of cathelicidin LL-37 by immune c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Infect Dis
Autors principals: Rekha, Rokeya Sultana, Mily, Akhirunnesa, Sultana, Tajnin, Haq, Ahsanul, Ahmed, Sultan, Mostafa Kamal, S. M., van Schadewijk, Annemarie, Hiemstra, Pieter S., Gudmundsson, Gudmundur H., Agerberth, Birgitta, Raqib, Rubhana
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6033279/
https://ncbi.nlm.nih.gov/pubmed/29973153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-018-3203-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars